Afrezza Rapid-Acting Inhaled Insulin Now Approved for Children and Adolescents With Type 1 Diabetes

Afrezza (inhaled mealtime insulin) was first approved for adults with diabetes in 2014. On May 29, 2026, the U.S. Food and Drug Administration (FDA) officially approved Afrezza for children and adolescents aged 6 and older. Inhaled insulin offers a needle-free alternative to managing mealtime blood sugar levels. If you are considering Afrezza for your child, it is important to understand how it works as well as its drawbacks and contraindications.

How Afrezza Works

Traditional rapid-acting insulin injections take time to absorb through the fat tissue beneath the skin. This creates a natural delay, which is why giving insulin before meals using an appropriate pre-bolus is important to catch the blood sugar rise. Traditional rapid-acting insulin peaks at about 1-3 hours after injection and clears from the body in about 5 hours.

Inhaled insulin uses a dry powder that bypasses the skin entirely. When inhaled, the insulin particles travel directly to the lungs, where they are quickly absorbed into the bloodstream.

Systemic insulin levels with Afrezza peak within 35 to 45 minutes, and the insulin clears the body within 1.5 to 3 hours. This drastically reduces the “tail” effect often seen with injected insulin, lowering the risk of low blood sugars hours after a meal has finished digesting.

Reviewing the Clinical Data

The clinical validation needed to approve Afrezza for minors came from a Phase 3 study called the INHALE-1 trial. The study evaluated 230 pediatric participants aged 4 to 17 who were randomly assigned to use either inhaled insulin or standard mealtime injections while keeping their usual long-acting basal insulin.

The trial proved that inhaled insulin was just as effective at lowering A1c​ levels over a 26-week period as traditional injections. Continuous glucose monitor metrics, specifically time in range of 70 to 180 mg/dL, were also comparable between the two groups.

Researchers also noted additional benefits, including improved weight management and higher treatment satisfaction scores among both participants and their caregivers.

Is Afrezza Safe?

Because this delivery method relies on the lungs, using a dry powder requires respiratory screening to ensure long-term safety. In clinical trials, the most common side effect reported was a temporary, mild cough, which typically occurred shortly after inhalation and improved as the child mastered the breathing technique.

To protect long-term lung health, the FDA enforces specific screening guidelines:

• Baseline spirometry: Before starting, pediatric patients must undergo a simple breathing test (spirometry) to confirm healthy baseline lung function.
• Routine monitoring: This lung function test must be repeated after the first six months of therapy, and annually thereafter.
• Contraindications: Inhaled insulin is contraindicated for pediatric patients with chronic respiratory conditions, including asthma or reactive airway disease, as the dry powder could trigger an asthma attack.

Practical Implications

There are clear advantages to using Afrezza for children and adolescents. Between unpredictable school lunches, spontaneous snacking, and sports or other activities, a child’s schedule is often unpredictable.

Because of its rapid onset, inhaled insulin is designed to be taken at the exact moment food intake begins, or even within the first few minutes of a meal, eliminating the need for pre-meal planning. It is also helpful for quickly correcting high blood sugar levels with a lower risk of insulin stacking.

Dosing is currently the biggest challenge. Inhaled insulin is available in fixed cartridges of 4, 8, and 12 units at this time (which are roughly equal to 2, 4, and 6 units of injected insulin, respectively). The lack of smaller doses means that younger children who require highly precise, small doses (such as half-units) may find it difficult to use.

Final Thoughts

While inhaled insulin does not replace the need for long-acting basal insulin or frequent monitoring, it provides an effective, noninvasive alternative to mealtime injections for children aged 6 and older, allowing for more flexibility and improved quality of life.